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Abstract
Background: Immune thrombocytopenia (ITP) is an immune-mediated acquired disease that is characterized by a
decrease in the platelet count and an increased risk of bleeding. There is little information in the literature about the
results of major joint replacement surgery in patients with ITP. The aim of this study was to report on the results of
total hip arthroplasty (THA) in patients with primary ITP.
Methods: We retrospectively identified 15 THAs performed in 11 patients with primary ITP. The study group was
matched (1:2) to a non-ITP control group of 30 THAs in 22 patients. According to the perioperative hematologic
evaluation, blood management interventions were performed. All procedures were performed by a single surgeon and all
patients received cementless components with ceramic-on-ceramic bearing. Mean duration of follow-up was 7.1 years
(range, 2–13).
Results: No significant differences were found between the two groups with regard to mean operative time,
intraoperative blood loss, amount of closed suction drainage, length of hospital stay, and readmission rate.
However, the proportion of patients requiring transfusion of packed red blood cells and/or platelet concentrate
was higher in the ITP group when compared to the non-ITP group. Mean Harris hip score improved from 49.5
points preoperatively to 93.4 points at the final follow-up and no hips were revised for loosening or osteolysis in
the ITP group. No significant differences were found between the two groups with respect to mean
postoperative Harris hip scores and complication rates.
Conclusions: Our study showed encouraging clinical and radiographic results of THA in patients with ITP without
increased risk of adverse events compared to those in patients without ITP. On the basis of these findings, we
suggest that modern cementless THA might be a viable treatment for achieving functional improvement in
patients with ITP and end-stage hip disease.
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Background
Immune thrombocytopenia (ITP) is an immune-
mediated acquired disease characterized by a transient
or persistent decrease in platelet count and an increased
risk of bleeding [1–3]. According to the International
Working Group (IWG) criteria, primary ITP is defined
as an autoimmune disorder characterized by isolated
thrombocytopenia (peripheral blood platelet count of
<100 × 109/L) in the absence of other causes or disor-
ders that might be associated with thrombocytopenia
[1]. Corticosteroids are widely accepted as the most ap-
propriate first-line treatment for ITP patients [2, 3],
and in such patients, the prevalence of steroid-induced
avascular necrosis lies between 9 % and 40 % with the
femoral head being the most commonly affected site
[4]. Furthermore, the prevalence of osteoarthritis of the
hip is increasing [5, 6], and thus, the number of elderly
ITP patients requiring total hip arthroplasty (THA) can
be expected to rise.
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Patients with ITP undergoing surgery are at increased
risk of adverse perioperative events, particularly if blood or
blood product transfusions are required preoperatively, or
if the surgical procedure is performed on an emergency
basis [7]. Furthermore, because greater perioperative blood
loss may be expected in patients with ITP undergoing
THA, and because of the additional risk of peripros-
thetic infection, special medical management is re-
quired to minimize complications in patients with ITP
undergoing THA. However, little information is avail-
able in the literature concerning the results of major
joint replacement surgery in patients with ITP, being
limited to isolated English and non-English language
case reports [8–10]. Accordingly, questions remain as
to whether patients with ITP can safely undergo THA,
as these patients may be at increased risk of surgical
complications and mortality [7, 11].
Therefore, the primary aim of this study was to report
on the clinical and radiographic outcomes of THA in
patients with primary ITP, and the secondary aim was to
determine whether patients with and without ITP differ
with respect to early postoperative outcomes, Harris hip
scores, and radiographic results.
Methods
We retrospectively reviewed the medical records of 11
consecutive patients with primary ITP who underwent
15 cementless THAs between 2001 and 2011 at our in-
stitution. Primary ITP was diagnosed according to the
IWG criteria [1] after thorough hematologic evaluation,
including consultation with a hematologist. All THA
candidates underwent complete blood count screening. In
patients with a low platelet count (<100 × 109/L) the fol-
lowing investigations were performed: reticulocyte counts,
estimation of red blood cell and thrombocyte indices,
bone marrow cytology (if thrombocytopenia had persisted
for > 6 months), thyroid stimulating hormone (TSH), as-
partate aminotransferase (AST), alanine aminotransferase
(ALT), gamma-glutamyl transpeptidase (GGT), creatinine,
blood urea nitrogen (BUN), lactate dehydrogenase (LDH),
bilirubin, Coombs test, antiphospholipid antibodies, im-
munoglobulin subclass analysis, von Willebrand antigen
and ristocetin cofactor, and serologic tests for hepatitis B
and C, human immunodeficiency virus (HIV), Epstein-
Barr virus (EBV), and cytomegalovirus (CMV). Two of the
eleven patients were diagnosed with ITP as a result of the
preoperative hematologic evaluation. The other nine had
already been diagnosed with chronic ITP and had been
previously managed by a hematologist. None of the pa-
tients with ITP were lost to follow-up, and all were in-
cluded in this study. This study protocol was approved by
the Review Board of Samsung Medical Center. Written in-
formed consent for participation in the study was obtained
from all patients.
Of the 11 patients (15 hips), 2 (2 hips) were male and 9
(13 hips) were female and they had an overall mean age of
49.3 years (range, 35–68 years) at the time of THA. The
mean time elapsed between ITP diagnosis and surgery
was 4.3 years (range, 0–13 years), and mean body mass
index (BMI) was 24.2 kg/m2 (range, 17.2–28.6 kg/m2).
Twelve hips (8 patients) were replaced because of osteo-
necrosis of the femoral head, and 3 hips (3 patients) were
replaced because of osteoarthritis. The mean American
Society of Anesthesiologists (ASA) score was 1.7
(range, 1–3), and mean follow-up was 7.1 years
(range, 2–13 years).
The 11 patients with ITP (15 hips) were matched (1:2)
with 22 patients without ITP (30 hips) with respect to:
patient age (±1 year), sex, preoperative diagnosis (osteo-
necrosis or osteoarthritis), and operating surgeon.
Demographic data of the ITP and non-ITP groups are
summarized in Table 1. No significant differences were
evident between the two groups with respect to age, sex,
BMI, etiology of THA, ASA scores, type of anesthesia,
or follow-up period (p > 0.05 for all).
In the ITP group, preoperative mean serum hemoglobin
was 11.7 g/dL (range, 7.7–15.1 g/dL) and mean platelet
count was 92.7 × 109/L (range, 34 × 109/L-149 × 109/L). At
time of surgery, mean platelet count was more than
100 × 109/L in 4 patients (5 hips) and less than this in
7 patients (10 hips). Packed red blood cells (pRBCs),
platelet concentrate (PC), and intravenous immunoglobu-
lin (IVIG) were transfused preoperatively based on the
results of hematological studies and hematologic consulta-
tions (Table 2). During the study period, we used the same
transfusion thresholds for both pRBCs and PC and/or
IVIG. A hemoglobin level of 8 g/dL was the transfusion
threshold for pRBCs [12, 13]. A platelet count of less than
80 × 109/L was the threshold for PC transfusion and/or
IVIG administration [14]. In the non-ITP control group,
mean preoperative serum hemoglobin was 12.6 g/dL
(range, 10.9-15.6 g/dL) and mean platelet count was
286 × 109/L (range, 111 × 109/L-357 × 109/L). No patient
in the non-ITP group required a blood transfusion pre-
operatively. No significant difference was found between
the two groups in preoperative serum hemoglobin level
(p = 0.211), but preoperative platelet count was signifi-
cantly lower in the ITP group (p = 0.001) than that in the
non-ITP group.
Operative treatment
All the operations were performed by a single surgeon in
the lateral position through an anterolateral approach.
Cementless components were used in all hips in both
groups. In the ITP group, the acetabular components used
were as follows; Bencox® cups (Corentec, Seoul, Korea;
n = 7), Duraloc® Option cups (DePuy/J&J, Warsaw, IN,
USA; n = 6), and SPH® Contact cups (Lima, Udin, Italy;
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n = 2). The femoral components used were Bencox®
stems (Corentec, Seoul, Korea; n = 7), S-ROM® stems
(DePuy/J&J, Warsaw, IN, USA; n = 6), and C2® stems
(Lima, Udin, Italy; n = 2). In all 22 hips, an alumina cer-
amic head and liner (Biolox® Forte, CeramTec AG,
Plochingen, Germany; n = 11 and Biolox® Delta, Ceram-
Tec AG, Plochingen, Germany; n = 4) were used (Fig. 1).
Twenty-eight millimeter heads were used in 10 hips,
32 mm in 4 hips, and 36 mm in 1 hip. In the non-ITP
group, the acetabular components used were as follows;
Bencox® cups (Corentec, Seoul, Korea; n = 9), Duraloc®
Option cups (DePuy/J&J, Warsaw, IN, USA; n = 17),
and SPH® Contact cups (Lima, Udin, Italy; n = 4). The
femoral components used were Bencox® stems (Corentec,
Seoul, Korea; n = 9), S-ROM® stems (DePuy/J&J, Warsaw,
IN, USA; n = 17), and C2® stems (Lima, Udin, Italy; n =4).
In all 30 hips, an alumina ceramic head and liner (Biolox®
Forte, CeramTec AG, Plochingen, Germany; n = 21 and
Biolox® Delta, CeramTec AG, Plochingen, Germany;
n = 9) were used. Twenty-eight millimeter heads were
used in 18 hips, 32 mm in 11 hips, and 36 mm in 1 hip.
Intra-operative blood loss was estimated by measuring the
volume of blood in the suction bottle, by weighing mops
and gauze pieces used during surgery, and by visual
Table 1 Demographics of the ITP and non-ITP groups
ITP Group Non-ITP Group p value
Number of patients (hips) 11 (15) 22 (30)
Mean age (years) 49.3 (35–68) 49.0 (35–68) 0.317
Sex (male/female) 2/13 4/26 1.000




Mean ASA score 1.7 (1–3) 1.4 (1–3) 0.160
Type of anesthesia 0.331
General 7 9
Spinal 8 21
Mean duration of follow-up (years) 7.1 (2–13) 7.2 (2–13) 0.285
ITP immune thrombocytopenia, ASA American Society of Anesthesiologists
Table 2 Perioperative Transfusions in the ITP Group
Case Diagnosis ASA PLT (×109/) Hb (g/dL) Preoperative transfusion (units) Postoperative transfusion (units)
1 ON 1 83 10.5 - PC, 4, pRBC 2
2 ON 2 98 11.3 - PC 6, pRBC 2
3 ON 3 52 7.7 PC 6, pRBC 2 PC 6, pRBC 4
4 OA 1 72 13.4 PC 8 -
5 OA 2 65 10.9 IVIG PC 8, pRBC 2
6 OA 2 71 13.4 PC 15
7 ON 3 55 11.7 IVIG, PC 12
8 ON 2 99 13.1 - pRBC 2
9 ON 2 131 14.1 - PC 8
10 ON 1 131 15.1 - -
11 ON 2 61 12.7 IVIG, PC 8 pRBC 2
12 ON 1 34 11.8 IVIG, PC 12 PC 8, pRBC 3
13 ON 2 143 9.4 -
14 ON 1 149 10.0 - pRBC 2
15 ON 1 146 10.8 - -
Mean 1.7 92.7 11.7 - -
ASA American Society of Anesthesiologists, PLT platelet, Hb haemoglobin, ON osteonecrosis, OA osteoarthritis, PC platelet concentrate, pRBC packed red blood cell,
IVIG intravenous immunoglobulin
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estimation of loss in the operative field. Hemostatic agents
such as tranexamic acid or fibrin sealant were not used
during the study period. Closed suction drains were rou-
tinely used in all patients.
Postoperative treatment
Both groups received the same postoperative manage-
ment, except that routine hematological tests were per-
formed more frequently in the ITP group. Drains were
removed 48 h after the operation and the drainage volume
was recorded as the post-operative blood loss. Mechanical
compression devices alone were used for deep vein throm-
bosis (DVT) prophylaxis in both groups without add-
itional pharmacological thromboprophylaxis because the
prevalence of venous thromboembolism in Korean pa-
tients without chemoprophylaxis had been reported to be
low at that time [15]. Antibiotic prophylaxis was admin-
istered to all patients starting 1 hour before surgery,
continuing until 3 days after surgery. Postoperatively,
hematological studies were performed in all patients
until hemoglobin and platelet levels reached and
remained at or above preoperative levels. Transfusions
were performed based on the results of hematological
studies and amounts of blood collected via suction
drains. The transfusion thresholds were hemoglobin
levels of 8 g/dL for pRBCs, and platelet count of 80 ×
109/L for PC for the entire postoperative period. All pa-
tients received the same postoperative rehabilitation.
All were allowed to stand on the second or third post-
operative day and to progress to partial weight bearing
with crutches as tolerated. Patients were allowed full
weight-bearing after 4 to 6 weeks.
Assessments
A single independent observer, who had not participated
in the operations, retrieved the following clinical data by
reviewing archived records: operative times, intraoperative
estimated blood losses, closed suction drainage amounts,
postoperative blood product transfusions (pRBC and PC),
durations of hospital stay, readmission rates, and compli-
cations. All patients were examined clinically at latest
follow-up visits. Harris hip scores [16] were used to assess
pain levels and function. Radiographic assessments were
performed immediately after surgery, and then at 6 weeks,
3 and 6 months, and at 1 year postoperatively, and then at
1 year or 2 year intervals until final follow-up visits. Radio-
graphic evaluations were performed by the same inde-
pendent observer. The 6 week postoperative radiographs
were used as references for radiographic evaluations of
component stability, wear, osteolysis, and loosening [17].
The stability of fixation of femoral and acetabular compo-
nents were classified as previously described [18, 19].
Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics version 22.0 (IBM Corp., Somers, NY, USA). The
Fig. 1 a Pre-operative radiograph showed osteonecrosis of the femoral head in patient with primary immune thrombocytopenia. b Preoperative
transfusions of six units of platelet concentrate and two units of packed red blood cells were performed. Postoperatively, six units of platelet
concentrates and four units of packed red blood cells were transfused. Post-operative radiograph of cementless total hip arthroplasty performed
with ceramic-on-ceramic bearing. c Twelve-year follow-up radiograph showed a well-fixed prosthesis with no osteolysis
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paired t test or the Wilcoxon matched pairs test was
used to analyze continuous variables, and McNemar's
chi square test was used to analyze dichotomous values.
Statistical significance was accepted for p values < 0.05.
Results
No significant differences were found between the ITP
and non-ITP groups with respect to mean operative time,
intraoperative estimated blood loss, closed suction drain-
age amount, duration of hospital stay, or readmission rates
(p > 0.05 for all). However, the two groups differed in
terms of postoperative blood management interventions.
The pRBC transfusion rate was higher in the ITP group
(p = 0.003), and the PC transfusion rate and total num-
ber of units of PC transfused were higher in the ITP
group (p = 0.001 for both). On the other hand, the total
number of units of pRBC transfused were not signifi-
cantly different between the two groups (p = 0.054),
In the ITP group, the mean Harris hip score improved
from 49.5 points (range, 37–61 points) to 93.4 points
(range, 90–100 points) at final follow-up. No significant
intergroup differences in postoperative Harris hip scores
were seen between groups (p = 0.163). In the ITP group,
no femoral or acetabular component showed radiographic
evidence of mechanical loosening, and no component had
been revised at final follow-up. Furthermore, no osteolysis
was observed, and no significant differences were found
between the two groups with respect to component stabil-
ity, osteolysis, or revision (p = 1.000 for all).
In the ITP group, no hip developed wound complica-
tions, deep infection or symptomatic venous thrombo-
embolism during follow-up, and no death occurred.
Furthermore, no ceramic fracture or squeaking was en-
countered. Complication rates were identical in the two
groups (p = 1.000).
Clinical and radiographic outcome data for both groups
are summarized in Table 3.
Discussion
Several previous studies demonstrated significantly higher
overall complication rates after a range of procedures
among patients with ITP, who were found to have consid-
erably higher risks of acute renal failure, postoperative
bleeding, septicemia, and pneumonia [7, 11]. Thus, at the
onset of this study, we postulated that major joint replace-
ment surgery in patients with ITP might be associated
with higher risks of perioperative bleeding, wound compli-
cations or periprosthetic infection. However, only limited
information was available about the outcomes of major
orthopedic surgery in patients with ITP [8–10]. Nezu
et al. described the case of a 42-year-old with refractory
ITP who underwent hip replacement under the cover of
vinca alkaloids and colchicine after their platelet count
was not sufficiently elevated by first or second line therapy
Table 3 Outcome data of the ITP and non-ITP groups
ITP Group (N = 15) Non-ITP Group (N = 30) p value
Mean operative time (minutes) 68.8 (49–104) 61.3 (43–104) 0.550
Mean intraoperative estimated blood loss (mL) 401 (100–1030) 375 (200–850) 0.115
Mean amount of suction drainage (mL) 526 (150–1040) 545 (220–980) 0.394
Number of patients transfused postoperatively
pRBC (%) 8 (53.3) 4 (13.3) 0.003
PC (%) 6 (40.0) 0 (0.0) 0.001
Mean number of units transfused postoperatively
pRBC 1.27 (0–4) 0.35 (0–4) 0.054
PC 2.67 (0–8) 0 0.001
Mean length of hospital stay (days) 9.5 (7–14) 9.2 (7–14) 0.445
Readmission rate (%) 0 0 1.000
Mean postoperative Harris hip score (points) 93.4 (90–100) 94.9 (92–100) 0.163
Number of patients experiencing post-operative complications
Component loosening 0 0 1.000
Osteolysis 0 0 1.000
Wound hematoma 0 0 1.000
Wound infection 0 0 1.000
Deep infection 0 0 1.000
Venous thromboembolism 0 0 1.000
Death 0 0 1.000
ITP immune thrombocytopenia, pRBC packed red blood cells, PC platelet concentrate
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[8]. Kim et al. described a series of five patients who
underwent total hip replacement for osteonecrosis of fem-
oral head associated with underlying ITP [9]. Singhal et al.
report the case of a 61-year-old with refractory ITP who
underwent total knee replacement [10]. However, no
case–control studies have been reported to date concern-
ing on patients with ITP who have undergone THA, and
no specific guidelines have been issued regarding the peri-
operative management of such patients. Therefore, in the
present study, we retrospectively analyzed the clinical and
radiographic results of THA in this patient population. In
particular, we analyzed operative times, intraoperative esti-
mated blood losses, closed suction drainage amounts,
postoperative blood product transfusions, hospital stay
durations, re-admission rates, and complications.
Most reports of the surgical treatment of patients with
ITP describe their management in the context of ab-
dominal surgery [11], which is generally characterized by
excellent intra-operative hemostasis. However, during
THA, difficult to control intraoperative and postopera-
tive bone bleeding is inevitable, and greater perioperative
blood loss can be expected. Nevertheless, in the present
study, perioperative blood losses, as determined by intra-
operative estimated blood losses and closed suction
drainage amounts, were not significantly different in the
ITP and non-ITP groups. We believe that this favorable
outcome might have resulted from relatively short op-
erative times and thorough perioperative blood manage-
ment interventions. All patients with ITP received pre-
operative transfusions/IVIG treatment if found to be at
high bleeding risk. The transfusion threshold for pRBCs
was a hemoglobin level of 8 g/dL, and for PC transfusion
and/or IVIG administration was a platelet count of 80 ×
109/L over the entire perioperative period. Furthermore,
we used mechanical compression devices only alone for
DVT prophylaxis, without additional pharmacological
thromboprophylaxis. These blood management strat-
egies were associated with excellent immediate postoper-
ative clinical courses and hospital stays similar to those
observed in the control group. However, an updated
meta-analysis of randomized trials showed that a re-
strictive transfusion strategy using a hemoglobin transfu-
sion trigger of < 7 g/dL results in a significant reduction
in acute coronary syndrome, pulmonary edema, rebleed-
ing, infections, and total mortality, compared with a
more liberal strategy [20]. Thus, if more restrictive trans-
fusion strategies had been used in the present study,
some of the patients in both groups might not have
needed the transfusions following THA. In addition,
new cost-effective blood management tools, such as
tranexamic acid or fibrin sealant, could be a promising
approach to reduce bleeding and consequently lead to
lower transfusion rates after total joint arthroplasty in
these patient populations [21, 22].
We found that the mean Harris hip score was 93.4 points
(range, 90 to 100 points) at a mean follow-up of 7.1 years
(range, 2–13 years) following cementless ceramic-on-
ceramic THA in patients with ITP. No abnormal
radiographic changes such as loosening or osteolysis
were observed at last follow-up, and no component
required revision. The excellent clinical and radio-
graphic outcomes achieved in the present study
might be due to the use of ceramic-on-ceramic ar-
ticulation combined with modern cementless THA
prostheses, which corroborates the findings of recent
clinical studies [23, 24].
Several limitations of the present study warrant con-
sideration. First, the study is limited by its retrospective
nature and by the small number of patients over a long
period of enrollment. These limitations might make it
difficult to accurately assess what the outcomes are of
this patient population. However, these limitations were
unavoidable owing to the rarity of ITP and the conse-
quent low number of patients with this condition who
undergo THA. Second, follow-up durations varied
widely. While all patients were followed for a minimum
of 2 years some were followed for as much as 13 years,
and the average follow-up was 7.1 years. Third, the var-
iety of implants used might have acted as a confounding
factor. Nevertheless, our study is unique in that it in-
volves a consecutive series of ITP patients treated using
modern cementless components in combination with
ceramic-on-ceramic bearings by a single surgeon at a
single institution. Fourth, contemporary blood manage-
ment strategies including the use of tranexamic acid or
fibrin sealant, and more restrictive blood transfusion
strategies were not used during the study period and
could further influence the results.
Conclusion
The present study describes encouraging early postoper-
ative outcomes of THA in patients with ITP, with no in-
crease in the risk of adverse events as compared with
THA in patients without ITP. In addition, excellent clin-
ical and radiographic results were obtained for all fifteen
cementless THAs performed in eleven ITP patients.
Based on these findings, we believe that modern cement-
less THA offers a viable means of achieving functional
improvements in patients with ITP and end-stage hip
disease without markedly increased perioperative risk. In
addition, we hope that our findings provide a reference
for surgeons who undertake major surgical interventions
in in patients with ITP.
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